Loading company…
Oncobit develops cancer monitoring diagnostics using circulating tumor-derived DNA.
Founded in 2018 and based in Schlieren, Switzerland, Oncobit develops cancer diagnostics, including its Oncobit™ PM monitoring platform, which analyzes blood samples for circulating tumor-derived DNA. Its tools support clinicians in monitoring treatment response and making therapy decisions. In November 2024, it raised CHF 1.47 million in PRE-SERIES A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in